
... BIBLIOGRAPHY ...

- Addington DE, Jones B, Bloom D, et al. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study. *Clin Ther* 1993; 15:917-926.
- Albright PS, Livingstone S, Keegan DL et al. Reduction of healthcare resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health linkable databases. *Clin Drug Invest* 1996;11:289-299.
- American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. *Am J Psychiatry* 1997;154(Suppl):3.
- Andreasen NC. Linking mind and brain in the study of mental illnesses: A project for a scientific psychopathology. *Science* 1997;275:1586-1593.
- Arvanitis LA, Miller BG and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. *Biol Psychiatry* 1997;42:233-246.
- Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: Implication for treatment outcome. *Acta Psychiatry Scand* 1994;89(Suppl 380):27-32.
- Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. *Eur Neuropharmacol* 1997;7:125-137.
- Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. *Psychopharmacol* 1996;124:159-167.
- Beasley CM, Tollefson GD, Tran PV. Efficacy of olanzapine: An overview of pivotal clinical trials. *J Clin Psychiatry* 1997;58(Suppl 10):7-12.
- Beasley CM Jr, Tollefson G, Tran PV, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. *Neuropsychopharmacol* 1996;14:111-123.
- Borison RL. Recent advances in the pharmacotherapy of schizophrenia. *Harvard Rev Psychiatry* 1997;4:255-271.
- Breier A, Buchanan R, Irish D, et al. Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns. *Hosp Community Psychiatry* 1993;44:1145-1149.
- Buchanan RW. Clozapine: Efficacy and safety. *Schizophren Bulletin* 1995;21:579-591.
- Carpenter WT. Serotonin-dopamine antagonists and treatment of negative symptoms. *J Clin Psychopharmacol* 1995;15(Suppl 1):30S-35S.
- Carpenter WT. The treatment of negative symptoms: Pharmacological and methodological issues. *Br J Psych* 1996;168(Suppl. 29):17-22.
- Carpenter WT, Buchanan RW. Schizophrenia. *N Engl J Med* 1994;330:681-690.
- Carpenter WT, Heinrich DW, Wagman AM. Deficit and non-deficit forms of schizophrenia: The concept. *Am J Psychiatry* 1988;145:578-583.
- Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. *Schizophren Bulletin* 1990;16:477-499.
- Chouinard G. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian Multicenter Risperidone Study. *J Clin Psychopharmacol* 1995;15(Suppl 1):36-44.
- De Leon J, Odom-White A, Stanilla J, Josiassen R, Simpson GM. Does clozapine induce akathisia? *Schizophrenia Research* 1995;15:206.
- DiMasi JA, Lasagna L. The economics of psychotropic drug development. In: Bloom FE, Kupfer DJ, eds. *Psychopharmacology: The Fourth Generations of Progress*. New York, NY: Raven Press 1995:1883-1895.
- Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. *Schizophren Bulletin* 1995;21:567-577.
- Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. *Schizophren Bulletin* 1997;23:583-609.
- Essock S, Hargreaves WA, Covell NH. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. *Psychopharmacol Bulletin* 1996;32: 683-697.
- Expert consensus guidelines for the treatment of schizophrenia. *J Clin Psych* 1996;57(Suppl 12B):1-58.
- Fulton B, Goa KL. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. *Drugs* 1997;53:281-298.
- Gallhofer B, Bauer U, Liss, et al. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. *Eur Neuropharmacol* 1996;6:52-13-52-20.
- Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. *J Clin Psychiatry* 1996;57:337-345.
- Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. *J Clin Psychiatry* 1997;58(Suppl 10):50-54.

- Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. *J Clin Psychiatry* 1993; 54:133-139.
- Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. *Harvard Rev Psychiatry* 1995;3:1-9.
- Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. *Schizophren Bulletin* 1997;23:567-582.
- Hoff AL. Neuropsychological function in schizophrenia. In: Shrikui CL, Nasrallah HA eds. *Contemporary Issues in the Treatment of Schizophrenia. 1st Edition*. American Psychiatric Press, Inc.;1995:187-208.
- Kane JM. What makes an antipsychotic "atypical"? Should the definition be preserved? *CNS Drugs* 1997;7: 347-348.
- Kane JM. Schizophrenia *N Engl J Med* 1996;334:34-41.
- Kane JM, Honigfeld G, Singer J, Meltzer HY for the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 1988; 45:789-796.
- Kane JM, Woerner M, Weinhold P, et al. Incidence of tardive dyskinesia: Five year data from a prospective study. *Psychopharmacol Bull* 1994;20:39-40.
- Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. *Am J Psychiatry* 1996; 153:366-476.
- Keck PE, McElroy SL. The new antipsychotics and their therapeutic potential. *Psychiatric Annals* 1997;5:320-331.
- Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. *J Clin Psychiatry* 1994;55(Suppl B):82-87.
- Lehman A, Ward J, Linn L. Chronic mental patients: The quality of life issues. *Am J Psychiatry* 1982;139:1271-1276.
- Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. *Arch Gen Psychiatry* 1990;47: 761-768.
- Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. *J Clin Psychiatry* 1996;57(Suppl 11):68-71.
- Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs: A review of compounds in use and development. *Br J Psych* 1993;163(Suppl 22): 7-18.
- Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia. *J Clin Psychiatry* 1996;57(Suppl 9):5-9.
- Lindstrom E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. *Clin Ther* 1995;17:402-412.
- Marder SR. Management of treatment-resistant patients with schizophrenia. *J Clin Psychiatry* 1996;57(Suppl 11): 26-30.
- Mattes JA. Risperidone: How good is the evidence for efficacy? *Schizophren Bulletin* 1997;23:155-161.
- Meltzer HY. Dimensions of outcome with clozapine. *Br J Psych* 1992;160(Suppl 17):46-53.
- Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review. *Br J Psychiatry* 1996; 168(Suppl 29):23-31.
- Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. *J Clin Psychopharmacology* 1995;15(Suppl 1): 25-35.
- Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: A review. *J Clin Psychiatry* 1994;55(9 Suppl B): 161-165.
- Meltzer H, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. *Am J Psychiatry* 1993;150:1630-1638.
- Miller R. Dose response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: Practical and theoretical implications. *Prog Neuropsychopharmacol Biol Psychiatry* 1997;21: 1059-1094.
- Möller HJ. The negative component in schizophrenia. *Acta Psychiatrica Scand* 1995;91(Suppl 388):11-14.
- National Advisory Mental Health Council. Healthcare reform for Americans with severe mental illness. *Am J Psychiatry* 1993;150:1447-1465.
- Packer S, Husted J, Cohen S, Tomlinson G. Psychopathology and quality of life in schizophrenia. *J Psychiatric Neurosci* 1997;22:231-234.
- Reid WH, Mason M, Toprac M. Savings in hospital bed days related to treatment with clozapine. *Hosp Community Psychiatry* 1994;45:261-264.

... BIBLIOGRAPHY ...

- Revicki DA, Luce BR, Wechsler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. *Hosp Community Psychiatry* 1990;41:850-854.
- Reynolds GP. What is an atypical antipsychotic? *J Psychopharmacol* 1997;11:195-199.
- Rice DP, Kelman, Miller LS. The economic burden of mental illness. *Hosp Community Psychiatry* 1992;43:1227-1232.
- Rice DP, Miller LS. The economic burden of schizophrenia: Conceptual and methodological issues and cost estimates. In: Moscovelli EM, Sartorius N. *Schizophrenia*. John Wiley and Sons; 1996.
- Rosenheck R, Charney DS, Frisman LK, et al. Clozapine's cost-effectiveness. *Am J Psychiatry* 1995;152:152-153.
- Rosenheck R, Cramer J, Weichun X, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. *N Engl J Med* 1997;337:809-815.
- Rupp A, Keith SJ. The costs of schizophrenia: Assessing the burden. *Psychiatry Clin North Am* 1993;16:413-423.
- Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment. *Arch Gen Psychiatry* 1997;54:453-463.
- Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. *J Clin Psychopharmacology* 1997;17:194-201.
- Somerai SB, McLaughlin TJ, Ross-Degnan D et al. Effects of limiting Medicaid drug-reimbursements benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. *N Engl J Med* 1994;331:650-655.
- Stip E. Memory impairment in schizophrenia: Perspectives from psychopathology and pharmacotherapy. *Can J Psychiatry* 1996;41(Suppl 2):275-345.
- Tandon R, DeQuardo JR, Goodson J, Mann NA, Greden JF. Effect of anticholinergics on positive and negative symptoms in schizophrenia. *Psychopharmacol Bulletin* 1992;28:297-302.
- Tandon R, Mann NA, Eisner, Coppard N. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. *Psychiatry Research* 1990;31:235-241.
- Testa MA, Simonson DC. Assessment of quality-of-life outcomes. *N Engl J Med* 1996;334:835-840.
- Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizophreniform disorders: Results of an international collaborative trial. *Am J Psychiatry* 1997;154:457-465.
- Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind placebo and haloperidol controlled clinical trial with olanzapine. *Am J Psychiatry* 1997;154:466-474.
- Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *J Clin Psychopharmacol* 1997;17:407-418.
- Umbricht D, Kane JM. Risperidone: Efficacy and safety. *Schizophren Bulletin* 1995;21:593-606.
- Viale G, Mechling L, Maislin G, et al. Impact of risperidone on the use of mental healthcare resources. *Psychiatric Services* 1997;48:1153-1159.
- Weiden PJ, Mott T, Cureio N. Recognition and management of neuroleptic noncompliance. In: Shriqui CL, Nasrallah HA eds. *Contemporary Issues in the Treatment of Schizophrenia. 1st Edition*. American Psychiatric Press, Inc.;1995:411-434.
- Weiden PJ, Olfson M. Cost of relapse in schizophrenia. *Schizophren Bulletin* 1995;21:419-429.
- Wyatt RJ. Neuroleptics and the natural course of schizophrenia. *Schizophren Bull* 1991;17:325-351.
- Yousef HA. A five year follow-up study of chronic schizophrenics and other psychotics treated in the community: Depot haloperidol decanoate versus other neuroleptics. *Advances in Therapy* 1989;67:186-195.
- Zimbroff DL, Kane JM, Tamminga CA, et al, for the Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. *Am J Psychiatry* 1997;154:782-791.